Dr. Al-Mudaiheem is an Advisor and Assistant Deputy Minister for Therapeutic Supportive Services, MOH, and Director of Drug Policy and Regulation Division. She is responsible for MoH formulary management and was recently appointed as Drug Policy and Regulation Manager and is a Board member of the Pharmacy Profession Society under SCFHS and of the Saudi Clinical Pharmacy Society.

Prof. Aljedai is the founding president of the Saudi Society of Clinical Pharmacy (SSCP), Riyadh, Saudi Arabia. He currently is the A. Deputy Minister for Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia. He is also a Professor at Al-Faisal University, School of Medicine and Pharmacy and the editor-in-chief of the Saudi Journal of Clinical Pharmacy.

Dr. Janahi co-founded Ana Fareed, a licensed health consultancy for advancing and revolutionizing the rare disease patient advocacy scenery in the GCC region. Adjacent Roles Founding Partner of Advance Health (2018 till Present) Chairman of UAE Pharma Business Group (2022 to Present) Past Chairman of UAE Rare Disease Society (2021 to 2022) Marwan holds a Bachelor’s degree in Business Administration from the University of Texas, USA and has completed the Future Leaders Program for UAE nationals in 2007 and Developing General Management Potential from Cranfield University in 2008. He also graduated from a program on general education from the American University of Dubai (AUD) and successfully finished the INSEAD – UAE Consortium for Executive Development Program in September 2015.

Dr. Al Qurayshah, is a Scientific Evaluation Expert at Saudi FDA with 15 years of experience. His primary responsibilities include leading efficacy and safety of oncology products. He is managing Orphan Drugs Designation project.

Prof. Alfadhel is the Deputy Executive Director of King Abdullah International Medical Research Centre, and Chairman of Genetics and Precision Medicine Department (GPM), Director of Medical Genomic Research Lab, King Saud Bin Abdulaziz University for Health Sciences.

Dr. Mariam is Head of the Molecular Genetics Laboratory at the Public Health Authority and Adjunct Assistant Professor at Alfaisal University's College of Medicine and a Principal Investigator (PI) at Alfaisal's AI Center and Ibn Khaldun Fellow at MIT's McGovern Institute for Brain Research in Cambridge, MA. Her areas of research include Population genetics, Genetics engineering and Bioinformatics.

Prof. Al-Muhaizea is a Professor at Alfaisal University, College of Medicine and a Consultant Pediatric Neurologist at King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. He has been practicing as pediatric neurologist with expertise in pediatric neuromuscular disorders, neuro-disability, and movement disorders. He is the founding chair of the National Saudi Pediatric Neurology Residency Program. Previously, he was the founding chair for the Saudi Pediatric Neurology training program. Currently, he serves as the chair of the examination committee under the Saudi Commission for Health specialties in Saudi Arabia.

Associate Professor in Medical Genetics, Director of the section of Medical Genetics at the University of Ferrara (Italy), and coordinator of the EU funded BIO-NMD project. She has accomplished profound research experience at the Universities of Bologna, Padova, Milan and Modena and published more than 120 scientific articles in international magazines.

Consultant Clinical Genetics, Head of Division Medical Genetics, Pediatric Departmen, Prince Sultan military Medical City, Riyadh, KSA

Presently, he is the CEO of Beyond Horizon Health, and serves as Chief Digital Health Officer and Head, Global Humanitarian Programs, Securra Health and a Fellow of both, Health Information and Management Systems Society (HIMSS) and American Academy of Family Physician and a Diplomate of, both, American Board of Preventive Medicine- Clinical Informatics and the American Board of Family Medicine.

Dr. Schaper is the CEO of the Australian Institute of Digital Health, holds a PhD in health informatics and is a Fellow of the International Academy of Health Sciences Informatics and the AIDH and is an in-demand speaker and writes for academic and industry publications.

Dr. Wong-Rieger is the Chair of Rare Disease International, Board member of Asia Pacific Rare Disease International, member of the Editorial Board of The Patient- Patient Centered Outcomes Research, member of the Global Commission to End the Diagnosis Odyssey for Rare Diseases and member of Health Technology Assessment International Patient /Citizen Involvement Interest Group.

Mr. Dant is the former Board Chair of the of the Washington DC based EveryLife Foundation for Rare Diseases and the former President and CEO of the National MPS Society. He founded the Ryan Foundation in 1992 shortly after their only child Ryan was diagnosed with MPS I.

She is an independent consultant to the life sciences industry having been in healthcare for over 25 years with the last 15 in rare diseases and commissioned rare disease service provision for NHS England and led the NICE Highly Specialized Technology program and has co-authored several papers that discuss challenges in rare diseases and HTA methods for assessing the value of orphan medicines and presented at many conference issue panels on the subject.